LPL Financial LLC Sells 6,773 Shares of Personalis, Inc. (NASDAQ:PSNL)

LPL Financial LLC trimmed its position in Personalis, Inc. (NASDAQ:PSNL) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 143,915 shares of the company’s stock after selling 6,773 shares during the quarter. LPL Financial LLC owned approximately 0.20% of Personalis worth $832,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Olympiad Research LP acquired a new stake in shares of Personalis in the fourth quarter valued at approximately $59,000. SG Americas Securities LLC bought a new position in Personalis during the fourth quarter worth $63,000. Raymond James Financial Inc. acquired a new position in shares of Personalis in the fourth quarter valued at $64,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Personalis in the fourth quarter valued at about $87,000. Finally, Barclays PLC lifted its stake in shares of Personalis by 45.4% during the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Personalis Stock Performance

NASDAQ:PSNL opened at $3.16 on Tuesday. The company has a market cap of $279.05 million, a price-to-earnings ratio of -1.88 and a beta of 1.89. Personalis, Inc. has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The stock has a fifty day moving average price of $3.88 and a 200-day moving average price of $4.53.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.09. The business had revenue of $16.80 million during the quarter, compared to analysts’ expectations of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Research analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on PSNL. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Personalis in a research report on Friday, February 28th. Craig Hallum initiated coverage on Personalis in a research note on Monday, March 17th. They issued a “buy” rating and a $8.00 price target for the company. Lake Street Capital increased their price objective on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $7.00 target price on shares of Personalis in a research report on Thursday, April 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $7.80.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.